Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab Group.
Adolescent
Age of Onset
Antirheumatic Agents
/ therapeutic use
Arabs
/ genetics
Arthritis, Juvenile
/ diagnostic imaging
Child
Child, Preschool
Consanguinity
Cross-Sectional Studies
Female
Heredity
Humans
Joints
/ diagnostic imaging
Male
Middle East
/ epidemiology
Pedigree
Predictive Value of Tests
Remission Induction
Risk Factors
Severity of Illness Index
Treatment Outcome
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
20
04
2020
accepted:
27
08
2020
pubmed:
5
9
2020
medline:
27
4
2021
entrez:
4
9
2020
Statut:
ppublish
Résumé
To report the cumulative articular and extraarticular damage in Arab children with juvenile idiopathic arthritis (JIA) and to identify variables that correlate with disease damage. We conducted a multicenter, cross-sectional study among 14 pediatric rheumatology centers from 7 Arab countries. JIA patients who met the International League of Associations for Rheumatology classification criteria and had a disease duration of >1 year were enrolled. Disease activity status was assessed using the Juvenile Arthritis Multidimensional Assessment Report. Disease damage was assessed by the Juvenile Arthritis Damage Index, articular (JADI-A) and extraarticular (JADI-E). A total of 702 (471 female) JIA patients with a median age of 11.3 years (interquartile range [IQR] 8.0-14.0 years) were studied. Median age at disease onset was 5 years (IQR 2.0-9.0 years) and the median disease duration was 4 years (IQR 2.0-7.0 years). The most frequent JIA categories were oligoarticular JIA (34.9%), polyarticular JIA (29.5%), and systemic JIA (24.5%). Clinical remission was achieved in 73.9% of patients. At the last clinic visit, 193 patients experienced joint damage, with a mean ± SD JADI-A score of 1.7 ± 4.5, while 156 patients had extraarticular damage, with a mean ± SD JADI-E score of 0.5 ± 1.1. Patients with enthesitis-related arthritis had the highest JADI-A score. JADI-A correlated significantly with the presence of a family history of JIA. JADI-A and JADI-E had a significant correlation with long disease duration. Cumulative damage was common in this Arab JIA cohort, and consanguinity and JIA in a sibling were frequent findings and were associated with a greater cumulative damage.
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-592Informations de copyright
© 2020, American College of Rheumatology.
Références
RavelliA, MartiniA. Juvenile idiopathic arthritis. Lancet2007;369:767-78.
HelmickCG, FelsonDT, LawrenceRC, GabrielS, HirschR, KwohCK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum2008;58:15-25.
DuffyCM, CollbertRA, LaxerRM, SchanbergLE, BoweyerSL. Nomenclature and classification in chronic childhood arthritis: time for a change?Arthritis Rheum2005;52:382-85.
PettyR, SouthwoodT, MannersP, BaumJ, GlassD, GoldenbergJ, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol2004;31:390-92.
WallaceCA, HuangB, BandeiraM, RavelliA, GianniniEH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum2005;52:3554-62.
GiancaneG, MuratoreV, MarzettiV, QuilisN, BenaventeB, BagnascoF, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther2019;8:21:168.
DeWittE. Outcomes research in childhood autoimmune diseases. Rheum Dis Clin North Am2013;39:921-33.
GlerupM, HerlinT, TwiltM. Clinical outcome and long-term remission in JIA. Curr Rheumatol Rep2017;19:75.
RavelliA. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol2004;22:271-5.
AdibN, SilmanA, ThomsonW. Outcome following onset juvenile idiopathic inflammatory arthritis. I: frequency of different outcomes. Rheumatology (Oxford)2005;44:995-1001.
RypdalV, ArnstadE, AaltoK, BerntsonL, EkelundM, FasthA, et al. Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study. Arthritis Res Ther2018;3:20:91.
MenonN, PeethambaranG, PuthiyapurayiA, NambudakathC, ArakkalR. Clinical profile and juvenile arthritis damage index in children with juvenile idiopathic arthritis: a study from a tertiary care center in south India. Int J Rheum Dis2018;21:871-9.
Al-MayoufSM, AldalaanH, AlfadaR, AlhaymouniB, AlshiakhM, EldaliA, et al. Long-term outcome of juvenile idiopathic arthritis in early adulthood: clinical experience from a Saudi tertiary hospital. JARR2018;1:1-6.
Al-MayoufSM, AlmutairiA, AlbrawiS, FathallaB, AlzyoudR, AlEnaziA, et al. Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG). Rheumatol Int2020;40:49-56.
RavelliA, MinoiaF, DavìS, HorneAC, BovisF, PistorioA, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol2016;68:566-76.
FoeldvariI, KlotscheJ, SimoniniG, EdelstenC, Angeles-Han S, BangsgaardR, et al. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC). Pediatr Rheumatol Online J2019;17:66.
BovisF, ConsolaroA, PistorioA, GarroneM, ScalaS, PatroneE, et al. Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatol Int2018;38:5-17.
Al-MayoufSM, AlE’edA, MuzafferM, ConsolaroA, BovisF, RupertoN. The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatol Int2018;38:43-9.
ViolaS, FeliciE, Magni-ManzoniS, PistorioA, BuoncompagniA, RupertoN, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum2005;52:2092-102.
YilmazM, KendirliS, AltintasD, KarakocG, InalA, KilicM. Juvenile idiopathic arthritis profile in Turkish children. Pediatr Int2008;50:154-8.
ConsolaroA, GiancaneG, AlongiA, vanDijkhuizenEH, AggarwalA, Al-MayoufSM, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health2019;3:255-63.
SarmaP, MisraR, AggarwalA. Physical disability, articular, and extra-articular damage in patients with juvenile idiopathic arthritis. Clin Rheumatol2008;27:1261-5.
Van DijkhuizenE, WulffraatN. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis2015;74:1996-2005.
SusicG, StojanovicR, PejnovicN, DamjanovN, SoldatovicI, JablanovicD, et al. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol 2011;29:337-44.
AlMarriM, QariA, Al-MayoufSM. Juvenile idiopathic arthritis in multiplex families: longitudinal follow-up. Int J Rheum Dis2017;20:898-902.
SarmaP, MisraR, AggarwalA. Outcome in patients with enthesitis related arthritis (ERA): Juvenile Arthritis Damage Index (JADI) and functional status. Pediatr Rheumatol Online J2008;22:6:18.
RumseyDG, GuzmanJ, RosenbergAM, HuberAM, ScuccimarriR, ShiffNJ, et al. Worse quality of life, function, and pain in children with enthesitis, irrespective of their juvenile arthritis category. Arthritis Care Res (Hoboken)2020;72:441-6.
NordalE, ZakM, AaltoK, BerntsonL, FasthA, HerlinT, et al. Ongoing disease activity and changing categories in a long-term Nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum2011;63:2809-18.
GiancaneG, AlongiA, RavelliA. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol2017;29:523-9.
BeukelmanT, PatkarNM, SaagKG, Tolleson-RinehartS, CronRQ, DeWittEM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken)2011;63:465-82.
WallaceCA, GianniniEH, SpaldingSJ, HashkesPJ, O’NeilKM, ZeftAS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum2012;64:2012-21.
RavelliA, ConsolaroA, HorneffG, LaxerR, LovellD, WulffraatN, et al. Treating juvenile idiopathic arthritis to target recommendations of an international task force. Ann Rheum Dis2018;77:819-28.